Your browser doesn't support javascript.
loading
Case report: Intraoperative thrombosis cardiac arrest in extended right hepatectomy involving use of local haemostatic agent in intraoperative cell salvage (ICS) and administration of recombinant activated factor VII (rFVIIa).
Kyang, Lee S; Howard, Andrew; Alzahrani, Nayef A; Morris, David L.
Afiliación
  • Kyang LS; Department of Surgery, St George Hospital, University of New South Wales, Sydney, New South Wales, Australia. Electronic address: lees.kyang@gmail.com.
  • Howard A; Department of Anaesthesia, St George Hospital, Sydney, New South Wales, Australia.
  • Alzahrani NA; Department of Surgery, St George Hospital, University of New South Wales, Sydney, New South Wales, Australia; College of Medicine, Al-Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
  • Morris DL; Department of Surgery, St George Hospital, University of New South Wales, Sydney, New South Wales, Australia.
Int J Surg Case Rep ; 57: 48-51, 2019.
Article en En | MEDLINE | ID: mdl-30901569
ABSTRACT

INTRODUCTION:

In modern surgical era, local haemostatic agents and blood components such as recombinant activated factor VII (rFVIIa) have expanded surgeons' armamentarium in controlling "surgical" and "nonsurgical bleeding". We report a case of intraoperative thrombosis and cardiac arrest involving use of local haemostatic agent in intraoperative cell salvage and rFVIIa administration in extended right hepatectomy. PRESENTATION OF CASE A 46-year-old lady underwent extended right hepatectomy using cardiopulmonary bypass (CPB) and autotransfusion with ICS for metastatic gastrointestinal stromal tumour. She became extremely coagulopathic following weaning of CPB despite an array of fluid and blood products replacements. Decision to administer rFVIIa as a measure to arrest bleeding was unsuccessful. Extensive systemic thrombosis occurred which resulted in cardiac arrest and mortality.

DISCUSSION:

The thromboembolic event was unclear but likely multifactorial. Two important hypotheses were the administration of rFVIIa and use of local haemostatic agent in ICS.

CONCLUSION:

Reported incidence of thromboembolism with use of rFVIIa in refractory bleeding is variable. More randomised controlled trials are needed to ascertain the efficacy and safety profile of the haemostatic agent. At present, off-label use of rFVIIa should be guided by the riskbenefit profile on a case-to-case basis. The authors also feel strongly against the use of local haemostatic gel in conjunction with ICS due to potential systemic circulation of the thrombin.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies / Qualitative_research Idioma: En Revista: Int J Surg Case Rep Año: 2019 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Prognostic_studies / Qualitative_research Idioma: En Revista: Int J Surg Case Rep Año: 2019 Tipo del documento: Article
...